Cargando…
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
Background: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results. In particular, the situation in patients who develop lupus anticoagu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623477/ https://www.ncbi.nlm.nih.gov/pubmed/34829374 http://dx.doi.org/10.3390/diagnostics11112027 |
_version_ | 1784605941996453888 |
---|---|
author | Úlehlová, Jana Piskláková, Barbora Ivanovová, Eliška Procházková, Jana Bradáčová, Pavla Kvasnička, Aleš Friedecký, David Slavík, Luděk |
author_facet | Úlehlová, Jana Piskláková, Barbora Ivanovová, Eliška Procházková, Jana Bradáčová, Pavla Kvasnička, Aleš Friedecký, David Slavík, Luděk |
author_sort | Úlehlová, Jana |
collection | PubMed |
description | Background: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results. In particular, the situation in patients who develop lupus anticoagulant (LA) antibodies is highly complex. To evaluate the effectiveness of DOAC therapy in lupus-positive patients, 31 samples were enrolled in this retrospective study. All patient samples were spiked with three types of DOAC (dabigatran, DABI; rivaroxaban, RIVA; and apixaban, API) in a concentration that significantly influenced the screening test for LA and thus can mask the presence of LA. Subsequently, the DOAC was always unbound by the DOAC-Stop procedure. DOAC levels before and after binding were determined by functional assays, followed by liquid chromatography coupled with mass spectrometry (LC-MS) analysis. Methods: The determination of DOAC levels was performed by direct thrombin assay and determination of anti-Xa activity with specific calibration as functional tests for DABI and xabans (API and RIVA). To determine concentration levels of API, DABI, and RIVA, our in-house LC-MS method was used. Results: The results of LA-positive samples show significant differences between functional tests and the LC-MS method both before and after DOAC binding. Conclusions: The acute findings of the presence of LA-type antibodies fundamentally affects the determination of DOAC by functional tests, and in this case, it is necessary to use LC-MS analysis to determine the true value. If patients treated with DOAC develop LA of medium and higher titers, we do not recommend checking DOAC levels with functional tests. |
format | Online Article Text |
id | pubmed-8623477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86234772021-11-27 Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients Úlehlová, Jana Piskláková, Barbora Ivanovová, Eliška Procházková, Jana Bradáčová, Pavla Kvasnička, Aleš Friedecký, David Slavík, Luděk Diagnostics (Basel) Article Background: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results. In particular, the situation in patients who develop lupus anticoagulant (LA) antibodies is highly complex. To evaluate the effectiveness of DOAC therapy in lupus-positive patients, 31 samples were enrolled in this retrospective study. All patient samples were spiked with three types of DOAC (dabigatran, DABI; rivaroxaban, RIVA; and apixaban, API) in a concentration that significantly influenced the screening test for LA and thus can mask the presence of LA. Subsequently, the DOAC was always unbound by the DOAC-Stop procedure. DOAC levels before and after binding were determined by functional assays, followed by liquid chromatography coupled with mass spectrometry (LC-MS) analysis. Methods: The determination of DOAC levels was performed by direct thrombin assay and determination of anti-Xa activity with specific calibration as functional tests for DABI and xabans (API and RIVA). To determine concentration levels of API, DABI, and RIVA, our in-house LC-MS method was used. Results: The results of LA-positive samples show significant differences between functional tests and the LC-MS method both before and after DOAC binding. Conclusions: The acute findings of the presence of LA-type antibodies fundamentally affects the determination of DOAC by functional tests, and in this case, it is necessary to use LC-MS analysis to determine the true value. If patients treated with DOAC develop LA of medium and higher titers, we do not recommend checking DOAC levels with functional tests. MDPI 2021-11-02 /pmc/articles/PMC8623477/ /pubmed/34829374 http://dx.doi.org/10.3390/diagnostics11112027 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Úlehlová, Jana Piskláková, Barbora Ivanovová, Eliška Procházková, Jana Bradáčová, Pavla Kvasnička, Aleš Friedecký, David Slavík, Luděk Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients |
title | Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients |
title_full | Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients |
title_fullStr | Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients |
title_full_unstemmed | Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients |
title_short | Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients |
title_sort | evaluation of the determination of dabigatran, rivaroxaban, and apixaban in lupus anticoagulant-positive patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623477/ https://www.ncbi.nlm.nih.gov/pubmed/34829374 http://dx.doi.org/10.3390/diagnostics11112027 |
work_keys_str_mv | AT ulehlovajana evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT pisklakovabarbora evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT ivanovovaeliska evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT prochazkovajana evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT bradacovapavla evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT kvasnickaales evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT friedeckydavid evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients AT slavikludek evaluationofthedeterminationofdabigatranrivaroxabanandapixabaninlupusanticoagulantpositivepatients |